Keywords: sustained, mm, responses, celgene, revlimid, drugmaker, reported

Sustained MM responses with Celgene's Revlimid

Article | 08 June 2009

Print This

US drugmaker Celgene reported data at the 14th Congress of the European Society of Hematology showing that Revlimid (lenalidomide) provides ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in